Literature DB >> 17379472

Hepatitis C management by addiction medicine physicians: results from a national survey.

Alain H Litwin1, Hillary V Kunins, Karina M Berg, Alex D Federman, Karyn K Heavner, Marc N Gourevitch, Julia H Arnsten.   

Abstract

Drug users are disproportionately affected by hepatitis C virus (HCV), yet they face barriers to health care that place them at risk for levels of HCV-related care that are lower than those of nondrug users. Substance abuse treatment physicians may treat more HCV-infected persons than other generalist physicians, yet little is known about how such physicians facilitate HCV-related care. We conducted a nationwide survey of American Society of Addiction Medicine physicians (n = 320) to determine substance abuse physicians' HCV-related management practices and to describe factors associated with these practices. We found that substance abuse treatment physicians promote several elements of HCV-related care, including screening for HCV antibodies, recommending vaccinations against hepatitis A and B, and referring patients to subspecialists for HCV treatment. Substance abuse physicians who also provide primary medical or HIV-related care were most likely to facilitate HCV-related care. A significant minority of physicians were either providing HCV antiviral treatment or willing to provide HCV antiviral treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379472      PMCID: PMC2929905          DOI: 10.1016/j.jsat.2006.12.001

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  33 in total

1.  Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.

Authors:  J Lorvick; A H Kral; K Seal; L Gee; B R Edlin
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

3.  Treatment of hepatitis C infection in injection drug users.

Authors:  M Backmund; K Meyer; M Von Zielonka; D Eichenlaub
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.

Authors:  Diana L Sylvestre; Alain H Litwin; Barry J Clements; Marc N Gourevitch
Journal:  J Subst Abuse Treat       Date:  2005-10

5.  Current care of hepatitis C-positive patients by primary care physicians in an integrated delivery system.

Authors:  D E Nicklin; C Schultz; C M Brensinger; J P Wilson
Journal:  J Am Board Fam Pract       Date:  1999 Nov-Dec

6.  Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.

Authors:  M N Gourevitch; D Hartel; P A Selwyn; E E Schoenbaum; R S Klein
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

7.  Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection.

Authors:  Holly Hagan; Shiela M Strauss; Janetta M Astone; Don C Des Jarlais
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

8.  Hepatitis C identification and management by family physicians.

Authors:  Elizabeth C Clark; Barbara P Yawn; James M Galliher; Jonathan L Temte; John Hickner
Journal:  Fam Med       Date:  2005-10       Impact factor: 1.756

9.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

10.  Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.

Authors:  Holly Hagan; Mary H Latka; Jennifer V Campbell; Elizabeth T Golub; Richard S Garfein; David A Thomas; Farzana Kapadia; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

View more
  16 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Successful integration of hepatitis C evaluation and treatment services with methadone maintenance.

Authors:  Kenneth A Harris; Julia H Arnsten; Alain H Litwin
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

3.  A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers.

Authors:  Diane S Morse; Miriam Schiff; Shabtay Levit; Rinat Cohen-Moreno; Geoffrey C Williams; Yehuda Neumark
Journal:  Subst Use Misuse       Date:  2012-01       Impact factor: 2.164

Review 4.  Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?: a narrative systematic review of the evidence base.

Authors:  Iain F Brew; Christine Butt; Nat Wright
Journal:  Br J Gen Pract       Date:  2013-12       Impact factor: 5.386

Review 5.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Authors:  Philip Bruggmann; Alain H Litwin
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

Review 6.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 7.  Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels.

Authors:  Jason Grebely; Megan Oser; Lynn E Taylor; Gregory J Dore
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

8.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Authors:  Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2008-11-28

Review 9.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

Review 10.  Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Authors:  Marija Zeremski; Jon E Zibbell; Anthony D Martinez; Steven Kritz; Bryce D Smith; Andrew H Talal
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.